Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLASH: 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment in mCRPC
2024-515604-39-00Phase 3Authorised
- Sponsor
- POINT Biopharma
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 6
01
Overview
Phase 3, randomised trial of Lu-PNT2002 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by POINT Biopharma. Primary endpoint: Radiological progression-free survival (rPFS). Planned start Nov 2024; status: authorised.
02
Drugs
Lu-PNT2002
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-515604-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515604-39-00.